<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39458042</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>20</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Outcomes and Healthcare Resource Utilization in Patients with COVID-19 Treated with Nirmatrelvir-Ritonavir: Real-World Data Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">6091</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13206091</ELocationID><Abstract><AbstractText><b>Background:</b> Nirmatrelvir-ritonavir was granted emergency use authorization in Israel in January 2022 to treat high-risk patients with mild-to-moderate COVID-19. The aim of the study was to assess the association between nirmatrelvir-ritonavir treatment and COVID-19-related hospitalization and healthcare resource utilization (HCRU) in a country with a high level of vaccinations compared to patients who were offered treatment and declined. <b>Methods:</b> The Maccabi Healthcare Services dataset was used to identify high-risk SARS-CoV-2-positive adults from January to February 2022 who received nirmatrelvir-ritonavir within 5 days of symptom onset (treatment group) or who were offered nirmatrelvir-ritonavir treatment and declined it (reference group). COVID-19-related hospitalizations and all-cause mortality and HCRU within 30 days were compared between treatment and reference groups using inverse probability of treatment weighting. <b>Results:</b> Treatment and reference groups included 3460 (median age, 68.4 years) and 1654 (70.2 years) patients, respectively. Patients with ≥1 dose of COVID-19 vaccine accounted for 89.5% (treatment group) and 72.1% (reference group) of the total. Treatment was associated with a lower risk of COVID-19-related hospitalization (adjusted OR, 0.59 [95% CI, 0.41,0.83]). Results were similar by age group (18-64/≥65 years) and among patients with/without vaccination in the prior 180 days. There were 11 (0.3%) versus 11 (0.7%) deaths in the treatment and reference groups, respectively. Treated patients had lower inpatient HCRU and greater less intensive outpatient HCRU (e.g., telemedicine and emergency room visits). <b>Conclusions:</b> Nirmatrelvir-ritonavir treatment was associated with a reduced risk of COVID-19-related hospitalization and a shift to less intensive outpatient HCRU. Comparison with a reference group of nirmatrelvir-ritonavir-eligible patients who declined treatment enabled an unbiased outcome assessment. Real-world data gathered during the Omicron BA.1 variant wave of COVID-19 in Israel support the continued use of nirmatrelvir-ritonavir for high-risk adults of all ages, regardless of previous vaccinations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weil</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv 6812509, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tene</LastName><ForeName>Lilac</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv 6812509, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chodick</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5189-8995</Identifier><AffiliationInfo><Affiliation>Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv 6812509, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fallach</LastName><ForeName>Noga</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv 6812509, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansari</LastName><ForeName>Wajeeha</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-1910-5836</Identifier><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY 10017, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Distelman-Menachem</LastName><ForeName>Tal</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Pfizer, Herzeliya 4672509, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maor</LastName><ForeName>Yasmin</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-7258-3434</Identifier><AffiliationInfo><Affiliation>Infectious Disease Unit, E. Wolfson Medical Center, Halochamim 62, Holon 5822012, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medical and Health Sciences, Tel Aviv University, Ramat Aviv, P.O. Box 39040, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Contract with Maccabi Health Services</GrantID><Agency>Pfizer Inc. Israel</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">healthcare resource utilization</Keyword><Keyword MajorTopicYN="N">hospitalization</Keyword><Keyword MajorTopicYN="N">nirmatrelvir–ritonavir</Keyword><Keyword MajorTopicYN="N">outcomes</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList><CoiStatement>Clara Weil, Lilac Tene, Gabriel Chodick, and Noga Fallach have no declarations of interest to report. Wajeeha Ansari and Tal Distelman-Menachem are employees of Pfizer Inc. and may hold stock or stock options. Yasmin Maor has received writing fees from MHS; honoraria for lectures from Pfizer, MSD, Gilead, and Medison; honoraria for advisory board meetings from MSD; and travel grants from Pfizer.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39458042</ArticleId><ArticleId IdType="pmc">PMC11508699</ArticleId><ArticleId IdType="doi">10.3390/jcm13206091</ArticleId><ArticleId IdType="pii">jcm13206091</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Torge D., Bernardi S., Arcangeli M., Bianchi S. Histopathological Features of SARS-CoV-2 in Extrapulmonary Organ Infection: A Systematic Review of Literature. Pathogens. 2022;11:867. doi: 10.3390/pathogens11080867.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11080867</ArticleId><ArticleId IdType="pmc">PMC9415619</ArticleId><ArticleId IdType="pubmed">36014988</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  WHO Situational Report.  [(accessed on 21 September 2024)];2022  Available online:  https://covid19.who.int.</Citation></Reference><Reference><Citation>CDC  Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals.  [(accessed on 26 April 2022)];2022  Available online:  https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html.</Citation></Reference><Reference><Citation>Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs. Science. 2003;300:1763–1767. doi: 10.1126/science.1085658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1085658</ArticleId><ArticleId IdType="pubmed">12746549</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen D.R., Allerton C.M., Anderson A.S., Aschenbrenner L., Avery M., Berritt S., Boras B., Cardin R.D., Carlo A., Coffman K.J., et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586–1593. doi: 10.1126/science.abl4784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abl4784</ArticleId><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevrioukova I.F., Poulos T.L. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc. Natl. Acad. Sci. USA. 2010;107:18422–18427. doi: 10.1073/pnas.1010693107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1010693107</ArticleId><ArticleId IdType="pmc">PMC2973003</ArticleId><ArticleId IdType="pubmed">20937904</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J. Effect of Nirmatrelvir/Ritonavir versus Placebo on COVID-19─Related Hospitalizations and Other Medical Visits; Proceedings of the ID Week 2022; Washington, DC, USA. 19–23 October 2022.</Citation></Reference><Reference><Citation>Shu Y. GISAID: From vision to reality. Eurosrveillance. 2017;22:30494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5388101</ArticleId><ArticleId IdType="pubmed">28382917</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodcroft E. CoVariants: SARS-CoV-2 Mutations and Variants of Interest. 2021.  [(accessed on 22 December 2022)].  Available online:  https://covariants.org/</Citation></Reference><Reference><Citation>Mathieu E. Coronavirus Pandemic (COVID-19)-SARS-CoV-2 Sequences by Variant. 3 January 2022.  [(accessed on 22 December 2022)].  Available online:  https://ourworldindata.org/coronavirus#explore-the-global-situation.</Citation></Reference><Reference><Citation> [(accessed on 26 April 2022)].  Available online:  https://www.researchgate.net/figure/World-map-of-Pfizer-voluntary-licensing-of-Paxlovid_fig1_359810882.</Citation></Reference><Reference><Citation>Arbel R., Wolff Sagy Y., Hoshen M., Battat E., Lavie G., Sergienko R., Friger M., Waxman J.G., Dagan N., Balicer R., et al. Nirmatrelvir use and severe COVID-19 outcomes during the Omicron surge. N. Engl. J. Med. 2022;387:790–798. doi: 10.1056/NEJMoa2204919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204919</ArticleId><ArticleId IdType="pmc">PMC9454652</ArticleId><ArticleId IdType="pubmed">36001529</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganatra S., Dani S.S., Ahmad J., Kumar A., Shah J., Abraham G.M., McQuillen D.P., Wachter R.M., Sax P.E. Oral nirmatrelvir and ritonavir in nonhospitalized vaccinated patients with coronavirus disease 2019 (COVID-19) Clin. Infect. Dis. 2023;76:563–572. doi: 10.1093/cid/ciac673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac673</ArticleId><ArticleId IdType="pmc">PMC9452095</ArticleId><ArticleId IdType="pubmed">35986628</ArticleId></ArticleIdList></Reference><Reference><Citation>Najjar-Debbiny R., Gronich N., Weber G., Khoury J., Amar M., Stein N., Goldstein L.H., Saliba W. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin. Infect. Dis. 2023;76:e342–e349. doi: 10.1093/cid/ciac443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac443</ArticleId><ArticleId IdType="pmc">PMC9214014</ArticleId><ArticleId IdType="pubmed">35653428</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C., Au I., Lau K., Lau E., Cowling B., Leung G. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: A retrospective cohort study. Lancet Infect. Dis. 2022;22:1681–1693. doi: 10.1016/S1473-3099(22)00507-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00507-2</ArticleId><ArticleId IdType="pmc">PMC9401976</ArticleId><ArticleId IdType="pubmed">36029795</ArticleId></ArticleIdList></Reference><Reference><Citation>Wai A.K.C., Chan C.Y., Cheung A.W.L., Wang K., Chan S.C.L., Lee T.T.L., Luk L.Y.F., Yip E.T.F., Ho J.W.K., Tsui O.W.K., et al. Association of molnupiravir and nirmatrelvir-ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19. Lancet Reg. Health West. Pac. 2022;30:100602. doi: 10.1016/j.lanwpc.2022.100602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2022.100602</ArticleId><ArticleId IdType="pmc">PMC9532222</ArticleId><ArticleId IdType="pubmed">36212676</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip T.C.F., Lui G.C.Y., Lai M.S.M., Wong V.W.S., Tse Y.K., Ma B.H.M., Hui E., Leung M.K., Chan H.L.Y., Hui D.S.C., et al. Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients. Clin. Infect. Dis. 2023;76:e26–e33. doi: 10.1093/cid/ciac687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac687</ArticleId><ArticleId IdType="pmc">PMC9452147</ArticleId><ArticleId IdType="pubmed">36031408</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah M.M., Joyce B., Plumb I.D., Sahakian S., Feldstein L.R., Barkley E., Paccione M., Deckert J., Sandmann D., Gerhart J.L., et al. Paxlovid associated with decreased hospitalization rate among adults with COVID-19—United States, April–September 2022. MMWR Morb. Mortal. Wkly. Rep. 2022;71:1531–1537. doi: 10.15585/mmwr.mm7148e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7148e2</ArticleId><ArticleId IdType="pmc">PMC9721144</ArticleId><ArticleId IdType="pubmed">36454693</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-On Y.M., Goldberg Y., Mandel M., Bodenheimer O., Freedman L., Kalkstein N., Mizrahi B., Alroy-Preis S., Ash N., Milo R., et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N. Engl. J. Med. 2021;385:1393–1400. doi: 10.1056/NEJMoa2114255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114255</ArticleId><ArticleId IdType="pmc">PMC8461568</ArticleId><ArticleId IdType="pubmed">34525275</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel Ministry of Health  Ministry of Health Tariff.  [(accessed on 2 January 2022)];2022  Available online:  https://www.gov.il/he/Departments/DynamicCollectors/moh-price-list?skip=0.</Citation></Reference><Reference><Citation>Israel NIIo  Death Statistics.  [(accessed on 1 October 2021)];2022  Available online:  https://www.btl.gov.il/English%20Homepage/Pages/default.aspx.</Citation></Reference><Reference><Citation>Israel Central Bureau of Statistics  Characterization and Classification of Geographic Units by the Socio-Economic Level of the Population 2015, Publication No 1765.  [(accessed on 1 October 2021)];2015  Available online:  https://www.cbs.gov.il/he/publications/DocLib/2019/1765_socio_economic_2015/e_print.pdf.</Citation></Reference><Reference><Citation>Rossman H., Shilo S., Meir T., Gorfine M., Shalit U., Segal E. COVID-19 dynamics after a national immunization program in Israel. Nat. Med. 2021;27:1055–1061. doi: 10.1038/s41591-021-01337-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01337-2</ArticleId><ArticleId IdType="pubmed">33875890</ArticleId></ArticleIdList></Reference><Reference><Citation>Chodick G., Heymann A.D., Shalev V., Kookia E. The epidemiology of diabetes in a large Israeli HMO. Eur. J. Epidemiol. 2003;18:1143–1146. doi: 10.1023/B:EJEP.0000006635.36802.c8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:EJEP.0000006635.36802.c8</ArticleId><ArticleId IdType="pubmed">14758871</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalev V., Chodick G., Goren I., Silber H., Kokia E., Heymann A.D. The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization. Int. J. Cardiol. 2011;152:345–349. doi: 10.1016/j.ijcard.2010.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2010.08.002</ArticleId><ArticleId IdType="pubmed">20826019</ArticleId></ArticleIdList></Reference><Reference><Citation>Coresh J., Turin T.C., Matsushita K., Sang Y., Ballew S.H., Appel L.J., Arima H., Chadban S.J., Cirillo M., Djurdjev O., et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. Jama. 2014;311:2518–2531. doi: 10.1001/jama.2014.6634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.6634</ArticleId><ArticleId IdType="pmc">PMC4172342</ArticleId><ArticleId IdType="pubmed">24892770</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitzman D., Chodick G., Shalev V., Grossman C., Grossman E. Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel. Hypertension. 2014;64:501–507. doi: 10.1161/HYPERTENSIONAHA.114.03718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.114.03718</ArticleId><ArticleId IdType="pubmed">24958503</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn S.C., Hilyard K., Castaneda-Angarita N., Freimuth V.S. Public acceptance of peramivir during the 2009 H1N1 influenza pandemic: Implications for other drugs or vaccines under emergency use authorizations. Disaster Med. Public Health Prep. 2015;9:166–174. doi: 10.1017/dmp.2014.156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/dmp.2014.156</ArticleId><ArticleId IdType="pubmed">25882123</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida K., Solomon D.H., Kim S.C. Active-comparator design and new-user design in observational studies. Nat. Rev. Rheumatol. 2015;11:437–441. doi: 10.1038/nrrheum.2015.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2015.30</ArticleId><ArticleId IdType="pmc">PMC4486631</ArticleId><ArticleId IdType="pubmed">25800216</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson H.I., Wohl D.A., Fischer W.A., Bartelt L.A., van Duin D., Agil D.M., Browne L.E., Li K.P., Moy A., Eron J.J., et al. COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina. J. Antimicrob. Chemother. 2024;79:859–867. doi: 10.1093/jac/dkae042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkae042</ArticleId><ArticleId IdType="pmc">PMC10984939</ArticleId><ArticleId IdType="pubmed">38380946</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormuth C.R., Kim J.D., Fisher A., Piszczek J., Kuo I.F. Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 Complications. JAMA Netw. Open. 2023;6:e2336678. doi: 10.1001/jamanetworkopen.2023.36678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.36678</ArticleId><ArticleId IdType="pmc">PMC10546233</ArticleId><ArticleId IdType="pubmed">37782496</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham S., Nohria A., Neilan T.G., Asnani A., Saji A.M., Shah J., Lech T., Grossman J., Abraham G.M., McQuillen D.P., et al. Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week. J. Am. Coll. Cardiol. 2022;80:1912–1924. doi: 10.1016/j.jacc.2022.08.800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.08.800</ArticleId><ArticleId IdType="pmc">PMC9580069</ArticleId><ArticleId IdType="pubmed">36243540</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi C., Qiu L., Zhuo J., Fang Y., Wang L., Xia J., Wang S., Luo Q., Zhou K., Li Y., et al. Prevalence of inappropriate use of nirmatrelvir-ritonavir antiviral therapy in hospitalized patients: A multi-centre retrospective study in China. Int. J. Antimicrob. Agents. 2023;62:106857. doi: 10.1016/j.ijantimicag.2023.106857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2023.106857</ArticleId><ArticleId IdType="pmc">PMC10197429</ArticleId><ArticleId IdType="pubmed">37211263</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>